Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.
(2013) Journal of Clinical Oncology — Vol. 31, n° 30, p. 3764-3775 (2013)
Files
document.pdf
Restricted Access - Adobe PDF
- 568.48 KB
Details
- Authors
- Abstract
- ETS was significantly associated with long-term outcome in patients with KRAS wild-type mCRC treated first-line with chemotherapy plus cetuximab. Validation in prospective trials is required to assess the value of this on-treatment marker in the clinical decision-making process.
- Affiliations
Citations
Piessevaux, H., Buyse, M., Schlichting, M., Van Cutsem, E., Bokemeyer, C., Heeger, S., & Tejpar, S. (2013). Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. Journal of Clinical Oncology, 31(30), 3764-3775. https://doi.org/10.1200/JCO.2012.42.8532 (Original work published 2013)